Competitor Analysis: Pim Kinase Inhibitors

Competitor Analysis: Pim Kinase Inhibitors

Product description

The three Pim kinases are a small family of serine/threonine kinases regulating several signaling pathways that are fundamental to cancer development and progression. These proteins are constitutively active once transcribed. Pim kinases are critical downstream effectors of the ABL, JAK2, and Flt-3 oncogenes and are required by them to drive tumorigenesis.

The present Competitive Intelligence report about Pim Kinase Inhibitorsprovides a competitor evaluation in the field of small molecule- and siRNA/miRNA-based inhibitors of the Pim Kinase for the treatment of cancer as of September 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of small molecule and siRNA/miRNA inhibitors of the Pim Kinases. In addition, the report lists company-specific R&D pipelines of Pim Kinase inhibitors. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.